Please assess the completion status of the following clinical trial:

Trial Title: A Study of Fluzone® High-Dose Vaccine Compared With Fluzone® Vaccine In Elderly Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Aged ≥ 65 years on the day of vaccination~* Informed consent form signed and dated~* Able to attend all scheduled visits and to comply with all trial procedures.~Exclusion Criteria:~* Participation at the time of study enrollment (or in the 4 weeks preceding the trial vaccination), or planned participation during each year of the trial period, in another clinical trial investigating a vaccine, drug, medical device, or medical procedure (Note: Concomitant participation in an observational trial is acceptable)~* Vaccination against influenza in the 6 months preceding the trial vaccination~* Systemic hypersensitivity to eggs, chicken proteins, or any of the vaccine components, or a history of a life-threatening reaction to Fluzone High-Dose or Fluzone vaccine or to a vaccine containing any of the same substances~* Personal history of Guillain-Barré Syndrome~* Dementia or any other cognitive condition at a stage that could interfere with following the trial procedures~* Thrombocytopenia contraindicating intramuscular (IM) vaccination, as judged by the investigator~* Bleeding disorder or receipt of anticoagulants in the 3 weeks preceding inclusion, contraindicating intramuscular vaccination, as judged by the investigator~* Current alcohol abuse or drug addiction~* Subject deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized involuntarily~* Identified as an Investigator or employee of the Investigator or study center with direct involvement in the proposed study, or identified as an immediate family member (i.e., parent, spouse, natural or adopted child) of the Investigator or employee with direct involvement in the proposed study~* Moderate or severe acute illness with or without fever (oral temperature \> 99.0ºF \[\> 37.2ºC\]). If this contraindication exists, vaccination will be deferred until the individual has been medically stable and/or afebrile (temperature ≤ 99.0 ºF \[≤ 37.2ºC\]) for at least 24 hours~* Signs and symptoms of an acute infectious respiratory illness. If this exists, vaccination will be deferred until the symptoms resolve.

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- High Dose Trivalent Inactivated Influenza Vaccine (Type: EXPERIMENTAL): Participants will receive an injection of High Dose Trivalent Inactivated Influenza Vaccine
- Trivalent Inactivated Influenza Vaccine (Type: ACTIVE_COMPARATOR): Participants will receive an injection of the Trivalent Inactivated Influenza vaccine

Based on this trial design, predict the completion outcome and termination type (if applicable).